Skip to main content
SpringerLink
Log in

Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy

  • Protocol
  • First Online:
Hemostasis and Thrombosis

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2663))

Abstract

This chapter will describe a method for measuring endogenous and infused Factor VIII (FVIII) in patients on emicizumab therapy (Hemlibra, Genetec, Inc). Emicizumab is a bispecific monoclonal antibody used in patients with hemophilia A, with or without inhibitors. The mechanism of action for emicizumab is novel and mimics the role that FVIII plays in vivo by binding and bridging FIXa and FX. It is vital that the laboratory understands the effect this drug has on coagulation tests and uses a suitable chromogenic assay which is not affected by emicizumab, for determination of FVIII coagulant activity and inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K (2018) For the subcommittee on Factor VIII, Factor IX and rare bleeding disorders. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. J Thromb Haemost 16:2530–2533. https://doi.org/10.1111/jth.14315

    Article  CAS  PubMed  Google Scholar 

  2. Parquet-Gernez A, Mazurier C, Goudemand M (1988) Functional and immunological assays of FVIII in 133 haemophiliacs- characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays. Thromb Haemost 59(2):202–206

    Article  CAS  PubMed  Google Scholar 

  3. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV (1994) Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol 87(4):846–848. https://doi.org/10.1111/j.1365-2141.1994.tb06749.x

    Article  CAS  PubMed  Google Scholar 

  4. Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV (1996) Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 94(2):400–406. https://doi.org/10.1046/j.1365-2141.1996.d01-1792.x

    Article  CAS  PubMed  Google Scholar 

  5. Duncan EM, Rodgers SE, McRae SJ (2013) Diagnostic testing for mild Haemophilia A in patients with discrepant one-stage, two-stage and chromogenic FVIII:C assays. Semin Thromb Hemost 39(3):272–282. https://doi.org/10.1055/s-0033-1334863

    Article  CAS  PubMed  Google Scholar 

  6. Bowyer AE, Van Veen JJ, Goodeve AC, Kitchen S, Makris M (2013) Specific and global coagulation assays in the diagnosis of discrepant mild haemophilia A. Haematologica 98(12):1980–1987. https://doi.org/10.3324/haematol.2013.08808

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bowyer AE, Goodeve A, Liesner R, Mumford AD, Kitchen S, Makris M (2011) p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it. Br J Haematol 154(5):618–625. https://doi.org/10.1111/j.1365-2141.2011.08688.x

    Article  PubMed  Google Scholar 

  8. Lyall H, Hill M, Westby J, Grimley C, Dolan G (2008) Tyr346→Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype – is this mild haemophilia A? Haemophilia 14(1):78–80. https://doi.org/10.1111/j.1365-2516.2007.01557.x

    Article  CAS  PubMed  Google Scholar 

  9. Rodgers SE, Duncan EM, Sobieraj-Teague M, Lloyd JV (2009) Evaluation of three automated chromogenic FVIII kits for the diagnosis of mild discrepant haemophilia A. Int J Lab Hematol 31(2):180–188. https://doi.org/10.1111/j.1751-553X.2007.01021.x

    Article  CAS  PubMed  Google Scholar 

  10. Rodgers SE, Duncan EM (2017) Chromogenic factor FVIII assays for improved diagnosis of haemophilia A. Methods Mol Biol 1646:265–267. https://doi.org/10.1007/978-1-4939-7196-1

    Article  CAS  PubMed  Google Scholar 

  11. Pipe S, Shima M, Lehle M et al (2019) Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, nonrandomised phase 3 study. Lancet 6:e295. https://doi.org/10.1016/S2352-3026(19)30054-7

    Article  Google Scholar 

  12. Lenting PJ, Denis CV, Christophe OD (2017) Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood 7 130(23):2463–2468. https://doi.org/10.1182/blood-2017-08-801662

    Article  CAS  Google Scholar 

  13. Shima M, Hanabusa H, Taki M (2016) Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 374(21):2044–2053

    Article  CAS  PubMed  Google Scholar 

  14. Bowyer A, Kitchen S, Maclean R (2020) Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors. Haemophilia 26(3):536–542. https://doi.org/10.1111/hae.13990

    Article  CAS  PubMed  Google Scholar 

  15. Jenkins et al (2020) Laboratory coagulation tests and emicizumab treatment: UK haemophilia centre doctors’ organisation guideline. Haemophilia 26:151–155. https://doi.org/10.1111/hae.13903

    Article  PubMed  Google Scholar 

  16. Adamkewicz JI, Chen DC, Paz-Priel I (2019) Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 119(7):1084–1093. https://doi.org/10.1055/s-0039-1688687

    Article  PubMed  Google Scholar 

  17. Srivastava A, Santagostino E, Dougall A et al (2020) (2020) WFH guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 26(Suppl 6):1–158. https://doi.org/10.1111/hae.14046

    Article  PubMed  Google Scholar 

  18. Adamkewicz J, Kim B, Steinbusch D, Calatzis A (2017) Measurement of FVIII inhibitor titer using a Chromogenic Bethesda Assay (CBA) in the presence of Emicizumab (ACE 910), a humanized bispecific antibody mimicking FVIIIa cofactor function. Haemophilia 23:3. (Abstract). https://doi.org/10.1111/hae.13217

    Article  Google Scholar 

  19. Miller CH, Boylan B, Payne AB, Driggers J, Bean CJ (2021) Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab. Int J Lab Hematol 43(2):84–86. https://doi.org/10.1111/ijlh.13384

    Article  Google Scholar 

  20. Rodgers SE, Duncan EM, Barbulescu DM, Quinn DM, Lloyd JV (2007) In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results. Br J Haematol 136(1):138–145. https://doi.org/10.1111/j.1365-2141.2006.06402.x

    Article  CAS  PubMed  Google Scholar 

  21. Biophen FVIII:C. Official product information (2015) Hyphen biomed. Neuille-Sur-Oise, France. D750 02 B1 1406

    Google Scholar 

  22. Factor VIII Chromogenic Assay Instruction for Use (2017) Siemens healthcare diagnostics products GmbH, Marburg Germany. B4238G40E11 Rev. 04 – en

    Google Scholar 

  23. Chromogenix Coamatic FVIII. Official product information. Updated 2019. Instrumentation Laboratory Company – Bedford, MA https://diapharma.com/wp-content/uploads/2021/01/K822585-Chromogenix-Coamatic-Factor-VIII-insert-302143-Rev-R6-03-2019-.pdf. Accessed 24 Aug 2022

  24. TCoag TriniCHROM Factor VIII:C Official product information (2016) TCoag Ireland Ltd, Wicklow, Ireland. 200645 09/2016

    Google Scholar 

  25. Ovanesov MV, Jackson JW, Golding B et al (2021) Considerations on activity assay discrepancies in factor VIII and factor IX products. J Thromb Haemost 19:2102–2111. https://doi.org/10.1111/jth.15425

    Article  CAS  PubMed  Google Scholar 

  26. Duncan EM, Collecutt M, Street A (2013) Nijmegen-Bethesda assay to measure FVIII inhibitors methods. Mol Biol 992:321–333. https://doi.org/10.1007/978-1-62703-339-8_24

    Article  CAS  Google Scholar 

  27. Bohm M, Taschner S, Kretzschmar E et al (2006) Cold storage of citrated whole blood induces dramatic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease. Blood Coagul Fibrinolysis 17(1):39–45. https://doi.org/10.1097/01.mbc.0000198990.16598.85

    Article  CAS  PubMed  Google Scholar 

  28. CLSI Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation assays and molecular Hemostasis Assays; Approved Guideline- Fifth addition (2008) CLSI Document H21-A5. Clinical and Laboratory Standards Institute, Wayne, PA

    Google Scholar 

  29. Mackie I, Cooper P, Lawrie A et al (2013) Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 35:1–13. https://doi.org/10.1111/ijlh.12004

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haematology, SA Pathology, Royal Adelaide Hospital, Adelaide, SA, Australia

    Olivia A. Yacoub & Elizabeth M. Duncan

Authors
  1. Olivia A. Yacoub
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth M. Duncan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivia A. Yacoub .

Editor information

Editors and Affiliations

  1. School of Medical Sciences, Faculty of Medicine and Health University of Sydney, Westmead Hospital, Westmead, NSW, Australia

    Emmanuel J. Favaloro

  2. Hemostasis & Thrombosis Center, University of California, Davis, Sacramento, CA, USA

    Robert C. Gosselin

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Yacoub, O.A., Duncan, E.M. (2023). Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy. In: Favaloro, E.J., Gosselin, R.C. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 2663. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3175-1_39

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-3175-1_39

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-3174-4

  • Online ISBN: 978-1-0716-3175-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation